Managing T-DXd-Related Toxicity and Intolerance in Later-Line HER2+ Breast Cancer

January 2, 2025

Opinion

Video

Panelists discuss how managing trastuzumab deruxtecan (T-DXd)–related toxicity and intolerance in later-line HER2+ breast cancer requires close monitoring, early detection of adverse effects like interstitial lung disease, and strategic adjustments to treatment regimens for improved patient safety and outcomes.

EP: 1.Overview of Clinical Data and Treatment Selection in Later-Line HER2+ Metastatic Breast Cancer

Now Viewing

EP: 2.Managing T-DXd-Related Toxicity and Intolerance in Later-Line HER2+ Breast Cancer

EP: 3.Third-Line Approach: 54-Year-Old Patient Treated With Tucatinib-Based Regimen

EP: 4.Evolving Landscapes: Personalized Approaches in Later-Line HER2+ Treatment

EP: 5.Strategic Screening and Management of Brain Metastases in HER2+ Breast Cancer

EP: 6.Intracranial Efficacy Data with With Tucatinib and T-DXd in Brain Metastases

EP: 7.Clinical Scenario: Tucatinib-Based Regimens in the Management of Brain Metastases in the 2nd-Line Metastatic Setting

EP: 8.Evolving Frontline Treatment Strategies and Future Directions in HER2+ Breast Cancer

EP: 9.Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!